Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 MajesTEC-9 study of TECVAYLI® ...

Company Announcement Based on the topline results from the EPCORE® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss ...

The combination of axi-cel and rituximab showed high efficacy in refractory LBCL, with a 73% complete response rate and 88% overall response rate. Safety was favorable, with no new signals; 96% ...

NHS England » Canakinumab for patients with Still’s disease refractory to anakinra and tocilizumab (adults and children 2 years and over) ...

Detailed price information for Actuate Therapeutics Inc (ACTU-Q) from The Globe and Mail including charting and trades.

QUILT-3.055 is a basket trial evaluating nogapendekin alfa inbakicept across multiple solid tumor types. In the NSCLC cohort, ...

Epcoritamab monotherapy achieved high overall (84.6%) and complete response rates (67.1%) in relapsed/refractory follicular lymphoma patients with multiple prior therapies. Combination therapy with ...

A new update from the American Gastroenterological Association (AGA) is calling for greater caution before surgery is ...

A new clinical practice update outlines a stepwise approach to diagnosing and managing refractory constipation before ...

Chronic constipation affects 8–12% of Americans. While most patients improve with conventional treatments, a small but ...